Back to List View Graph View

Histone deacetylase inhibitors

Histone deacetylase inhibitors (HDAC inhibitors, or HDACi) are therapeutic agents that inhibit histone deacetylase enzymes, thereby altering the acetylation state of histones and other cellular proteins.

Where the papers sit

11 papers from the last 6 months study histone deacetylase inhibitors directly · updated from PubMed 16 Nov 2026

  • HDAC Control of Cell Fate

    HDAC inhibition is being used to redirect differentiation and expose vulnerabilities in stem-like or lineage-committed cancer cells. Mocetinostat and tucidinostat recur in studies of refractory hematologic disease, including TFH-type PTCL. Other work links CoREST and KBTBD4 disruption to differentiation defects, while HDAC modulation suppresses hemangioma vasculogenesis. The shared direction is mechanistic rather than clinical: defining cell-state dependencies that can guide selective treatment.

    4 papers · 36.4%

  • HDAC Immunotherapy Sensitization

    HDAC inhibition is being paired with checkpoint blockade to overcome immune resistance in solid tumors. Entinostat and pembrolizumab recur in efforts to reshape suppressive circuits involving CD163-positive cells and improve response. NRAS-associated melanoma plasticity and metastatic breast cancer provide settings for testing this strategy. Drug-synergy workflows are becoming more standardized, but the predictive immune biomarkers remain unsettled.

    3 papers · 27.3%

  • Others — HDAC Targeting and Drug Discovery

    Structure-guided screening is being used to identify selective HDAC11 inhibitors, with Autodock Vina, PyMOL and molecular-dynamics analyses supporting compound design. Other studies examine HDAC-dependent p53 and histone acetylation, neuronal protection during hypoxia, and sensitization of HER2-positive tumors to antibody-drug conjugates. Nanatinostat appears among candidate agents, but the biological applications remain divergent. No single therapeutic direction unifies the cluster beyond pharmacological HDAC targeting.

    4 papers · 36.4%

PARADIGM SHIFT

HDAC inhibitors can produce therapeutic effects by redirecting cell fate rather than by direct cytotoxicity

The KBTBD4-mutant hematopoietic stem and progenitor-cell model and the infantile hemangioma stem-cell model both treat altered differentiation as the therapeutic target, rather than assuming that HDAC inhibition must primarily kill abnormal cells. In the KBTBD4 model, mocetinostat disrupted mutant KBTBD4–CoREST activity and relieved the resulting differentiation defect; in the hemangioma model, SAHA blocked pericyte differentiation, promoted adipogenic differentiation, and suppressed vasculogenesis. Together, these findings establish cell-fate control as an independently demonstrated therapeutic mechanism for HDAC inhibitors across distinct diseases and models 42576054Aug 42240910Jun.

NEW DIRECTION

HDAC inhibition is a neuroprotective intervention after ischemic stroke

The ischemic-stroke model treated with apicidin assigns HDAC inhibition a role outside the cancer and tumor-growth settings used by the other papers: preserving neuronal ultrastructure after reperfusion. Unlike DMOG, which offered little neuronal protection, apicidin preserved neuronal soma and improved synaptic and glial integrity, while vascular protection remained associated with HIF activation. This makes HDAC inhibition a component-specific neurovascular intervention rather than another antitumor or differentiation-directed application 42219139May.

Papers

The 11 papers from the last 6 months that study histone deacetylase inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

HDAC Control of Cell Fate (4)
  1. Cancer-associated KBTBD4 mutations induce differentiation defects and confer a unique therapeutic vulnerability. Cancer gene therapy · 10 Aug 2026 PMID 42576054
  2. TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial. International journal of hematology · 9 Jun 2026 PMID 42262647
  3. HDAC inhibition reprograms stem cell fate to suppress infantile hemangioma vasculogenesis. Angiogenesis · 4 Jun 2026 PMID 42240910
  4. Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma. eLife · 26 May 2026 PMID 42189716
HDAC Immunotherapy Sensitization (3)
  1. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
  2. Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer. Cancer research · 11 Aug 2026 PMID 42578817
  3. Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jun 2026 PMID 42224741
Others — HDAC Targeting and Drug Discovery (4)
  1. Structure-guided identification of histone deacetylase 11 inhibitors for targeted chemotherapy through long-timescale molecular dynamics simulation. Journal of molecular modeling · 16 Sept 2026 PMID 42747587
  2. Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
  3. Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139
  4. [Expression of Concern] Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. International journal of oncology · 22 May 2026 PMID 42169657

By study type

Clinical trials (1)
  1. TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial. International journal of hematology · 9 Jun 2026 PMID 42262647
Observational studies and case reports (1)
  1. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
Human data, design not indexed (3)
  1. Structure-guided identification of histone deacetylase 11 inhibitors for targeted chemotherapy through long-timescale molecular dynamics simulation. Journal of molecular modeling · 16 Sept 2026 PMID 42747587
  2. Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma. eLife · 26 May 2026 PMID 42189716
  3. [Expression of Concern] Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. International journal of oncology · 22 May 2026 PMID 42169657
Preclinical: animal, cell and lab studies (6)
  1. Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. Cell reports. Medicine · 13 Aug 2026 PMID 42594874
  2. Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer. Cancer research · 11 Aug 2026 PMID 42578817
  3. Cancer-associated KBTBD4 mutations induce differentiation defects and confer a unique therapeutic vulnerability. Cancer gene therapy · 10 Aug 2026 PMID 42576054
  4. HDAC inhibition reprograms stem cell fate to suppress infantile hemangioma vasculogenesis. Angiogenesis · 4 Jun 2026 PMID 42240910
  5. Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jun 2026 PMID 42224741
  6. Divergent neurovascular protection: Histone deacetylase inhibition preserves neuronal ultrastructure while hypoxia-inducible factor activation maintains vascular integrity after ischemic stroke. Brain research · 31 May 2026 PMID 42219139